Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Cancer Med. 2024 Sep;13(17):e70117. doi: 10.1002/cam4.70117.
Previous results about prognostic value of CD4+ T cells in follicular lymphoma (FL) remain controversial.
Immunohistochemistry was used to examine expression of positive CD4 cells in 103 patients with FL 1-3A. Early failure was described as failing to achieve event-free survival (EFS) at 12 or 24 months.
There were 49 (47.6%) male and 54 (52.4%) females, with a median age of 54 years. Compared to patients with <20% of positive CD4 cells, patients with ≥20% of positive CD4 cells exhibited a significant lower risk of early failure (2-year EFS rate: 56.7% vs 73.5%, p = 0.047). When patients were stratified based on positive CD4 cell combined with FLIPI, the median EFS (p = 0.002) and median OS (p = 0.007) were significantly different.
This study demonstrated that higher expression of positive CD4 cells predicts lower risk of early failure in follicular lymphoma, and combination analysis of CD4 and FLIPI could better predict disease relapse and survival outcome.
关于滤泡性淋巴瘤（FL）中 CD4+T 细胞的预后价值的先前结果仍存在争议。
采用免疫组织化学方法检测 103 例 FL1-3A 患者中阳性 CD4 细胞的表达。早期失败被描述为未能在 12 或 24 个月时达到无事件生存（EFS）。
男性 49 例（47.6%），女性 54 例（52.4%），中位年龄为 54 岁。与阳性 CD4 细胞<20%的患者相比，阳性 CD4 细胞≥20%的患者早期失败的风险显著降低（2 年 EFS 率：56.7% vs 73.5%，p=0.047）。当根据阳性 CD4 细胞与 FLIPI 联合分层时，中位 EFS（p=0.002）和中位 OS（p=0.007）存在显著差异。
本研究表明，阳性 CD4 细胞的高表达预示着滤泡性淋巴瘤早期失败的风险较低，CD4 和 FLIPI 的联合分析可以更好地预测疾病复发和生存结局。
